Replies to post #3663 on Rexahn Pharmaceuticals, Inc. (REXN)

[mypekeispooped]

Could be partially attributed to an analyst cutting price target but kept outperform rating.

https://www.smarteranalyst.com/2017/05/26/rexahn-pharmaceuticals-inc-rnn-challenged-financing-overhang-fbr-slashed-price-target/